1. Home
  2. BANL vs SABS Comparison

BANL vs SABS Comparison

Compare BANL & SABS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

BANL

CBL International Limited

N/A

Current Price

$6.00

Market Cap

19.0M

Sector

Energy

ML Signal

N/A

Logo SAB Biotherapeutics Inc.

SABS

SAB Biotherapeutics Inc.

HOLD

Current Price

$3.40

Market Cap

344.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BANL
SABS
Founded
2015
2014
Country
Malaysia
United States
Employees
N/A
N/A
Industry
Oil Refining/Marketing
Biotechnology: Pharmaceutical Preparations
Sector
Energy
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
19.0M
344.8M
IPO Year
2022
2020

Fundamental Metrics

Financial Performance
Metric
BANL
SABS
Price
$6.00
$3.40
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
$10.75
AVG Volume (30 Days)
60.7K
274.3K
Earning Date
04-17-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
78.53
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.27
$1.85
52 Week High
$16.40
$5.15

Technical Indicators

Market Signals
Indicator
BANL
SABS
Relative Strength Index (RSI) 38.17 38.47
Support Level $0.36 $3.38
Resistance Level $16.40 $4.02
Average True Range (ATR) 1.76 0.13
MACD -1.26 -0.04
Stochastic Oscillator 2.78 13.11

Price Performance

Historical Comparison
BANL
SABS

About BANL CBL International Limited

CBL International Ltd is a marine fuel logistics company that provides a one-stop solution for vessel refueling. In the bunkering industry, it is referred to as a bunkering facilitator. It facilitates vessel refueling between ship operators and local physical distributors/traders by purchasing marine fuel, including fossil fuel and alternative fuel, from its suppliers and arranging for the suppliers to deliver the fuel to the customers. The company's customer base comprises container liners, bulk carriers, and tankers. Geographically, the company generates a majority of its revenue from China, followed by Hong Kong, Malaysia, Singapore, South Korea, and other regions.

About SABS SAB Biotherapeutics Inc.

SAB Biotherapeutics Inc is a clinical-stage biopharmaceutical company focused on developing multi-specific, high-potency, human immunoglobulin G (hIgG) to treat and prevent immune and autoimmune disorders. The company's lead product candidate, SAB-142, targets autoimmune Type 1 Diabetes (T1D) with a disease-modifying therapeutic approach that aims to change the T1D treatment paradigm by delaying onset and potentially preventing disease progression of Stage 3 T1D patients. It is focused on developing product candidates for disease targets where a differentiated approach has the greatest potential to be either first-in-class against novel targets against complex targets to treat diseases, including type 1 diabetes (T1D) and other autoimmune disorders.

Share on Social Networks: